advertisement
Abstract #8089 Published in IGR 4-3
Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension
Shi JM; Jiang YQHunan Yi Ke Da Xue Xue Bao 2002; 27: 263-266
OBJECTIVE: To evaluate the efficacy and safety of 0.2% brimonidine administered in patients with glaucoma or ocular hypertension. METHODS: Twenty-five patients (41 eyes) with primary open-angle glaucoma or ocular hypertension were enrolled in this prospective study. Eye drops of 0.2% brimonidine were used twice daily for six months and the patients were examined each month after the treatment, including trough intraocular pressure (IOP, IOP 12 hours after 0.2% brimonidine was administered) and peak IOP (IOP 12 hours after 0.2% brimonidine was administered). The visual field was examined every three months. RESULTS: The use of 0.2% brimonidine significantly lowered trough IOP and peak IOP (p < 0.05). Each point of the IOP diurnal curve was significantly decreased compared with the baseline (p < 0.05). No significant change in the visual field was seen at three or six months after treatment with 0.2% brimonidine. No serious systemic side-effects were observed. CONCLUSIONS: Brimonidine is safe and effective in lowering IOP in glaucoma or ocular hypertension, and is well tolerated. LA: Chinese
J.M. Shi, MD, Department of Ophthalmology, Second Xiangya Hospital, Central University, Changsha 410011, China
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
